U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone954-835-1500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.70 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions
What is US Stem Cell's stock symbol?
US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."
How were US Stem Cell's earnings last quarter?
US Stem Cell Inc (OTCMKTS:USRM) posted its quarterly earnings data on Wednesday, August, 8th. The company reported $0.00 earnings per share (EPS) for the quarter. The company had revenue of $1.82 million for the quarter. View US Stem Cell's Earnings History.
When is US Stem Cell's next earnings date?
Has US Stem Cell been receiving favorable news coverage?
Press coverage about USRM stock has trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. US Stem Cell earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of US Stem Cell's key competitors?
Some companies that are related to US Stem Cell include HedgePath Pharmaceuticals (HPPI), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), Geovax Labs (GOVX), National Research (NRCIB), National Research (NRCIA), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY).
What other stocks do shareholders of US Stem Cell own?
Who are US Stem Cell's key executives?
US Stem Cell's management team includes the folowing people:
- Miguel Tomás, President, CEO, CFO & Director
- Kristin C. Comella, Director & Chief Scientific Officer
- Philip Posa, Senior Vice President-U.S. & International Sales
How do I buy shares of US Stem Cell?
Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is US Stem Cell's stock price today?
One share of USRM stock can currently be purchased for approximately $0.0210.
How big of a company is US Stem Cell?
US Stem Cell has a market capitalization of $8.26 million and generates $6.70 million in revenue each year.
What is US Stem Cell's official website?
How can I contact US Stem Cell?
US Stem Cell's mailing address is 13794 NW 4TH STREET SUITE 212, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]
MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)
MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
